Amgen reaffirms earnings outlook after hurricane hits Puerto Rico
After reviewing the impacts to its Puerto Rico manufacturing facility from Hurricane Maria, Thousand Oaks biotech giant Amgen reaffirmed its earnings outlook Sept. 25 and said that outreach to impacted staff was ongoing. The storm did not damage any product or in-process inventory at the plant, and the company said it did not expect any Read More →
FDA approves Amgen cancer treatment biosimilar Mvasi
The U.S. Food and Drug Administration approved a cancer treatment biosimilar developed in partnership between Allergan and Thousand Oaks-based Amgen, the company announced Sept. 13. Mvasi was approved to treat five types of cancer in combination with other therapies. “The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first Read More →
Our view: Congress should allow ‘dreamers’ to stay in U.S.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Study finds Amgen asthma drug is effective
An asthma drug being developed by Thousand Oaks-based Amgen and AstraZeneca showed significant yearly reduction for patients, according to a study published in the New England Journal of Medicine Sept. 6. Patients with severe, uncontrolled asthma using tezepelumab saw a drop in annual exacerbation compared with patients taking a placebo, Amgen said in a news Read More →
Our view: Sexual abuse bill would protect entrepreneurs from investors
Sen. Hannah-Beth Jackson (D-Santa Barbara) has been getting well-deserved national attention for a timely effort to address sexual abuse in the venture capital industry. She has introduced a draft of SB 224, a bill that aims to deter investors from making unwanted sexual advances to entrepreneurs seeking funding. Her effort comes at a time when Read More →
Amgen partnering with Humana to study diseases
Thousand Oaks biotechnology giant Amgen announced a collaboration agreement with Louisville, Ky.-based Humana on Aug. 17 to study conditions like cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer. The two companies currently have six projects underway focusing on improving health care quality and costs with data from Humana’s 13 million members, including wearable technology, Read More →
Amgen to pay $1.15 dividend to shareholders
The board of directors for Thousand Oaks biopharmaceutical giant Amgen approved at $1.15 dividend for the third quarter on July 28. Shareholders of record at the close of day on Aug. 17 will be paid the dividend on Sept. 8. • Contact Marissa Nall at mnall@pacbiztimes.com.
